Alternating noncross-resistant combination chemotherapy and active nonspecific immunotherapy with BCG or MER-BCG for advanced breast carcinoma

G. R. Blumenschein, G. N. Hortobagyi, S. P. Richman, J. U. Gutterman, C. K. Tashima, A. U. Buzdar, M. A. Burgess, Robert B Livingston, Evan M Hersh

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

One hundred fifty-six evaluable patients with metastatic breast cancer were treated with vincristine, Adriamycin and cyclophosphamide alternating at fixed intervals with 5-FU and methotrexate. Immunotherapy with BCG or MER-BCG was administered to all patients in two consecutive treatment programs. Overall objective response rate and complete response rate were 67% and 20%, respectively. These were not significantly different between the two immunotherapeutic groups. The median time to progression was sixteen-and-a-half months from initiation of therapy. The median survival of all patients was 21 months and that of responder was 26 months. Response rates, time to progression, and survival showed no significant advantage over a recent historical control group treated with FAC-BCG. Toxicitiy related to the gastrointestinal tract and bone marrow was considerably higher in this protocol than in the FAC combinations. MER at the dose, route, and schedule administered in this protocol caused excessive local and systemic toxic reactions. The alternative use of these noncross-resistant combinations in advanced breast cancer is not superior to combination chemotherapy used in the traditional manner.

Original languageEnglish (US)
Pages (from-to)742-749
Number of pages8
JournalCancer
Volume45
Issue number4
DOIs
StatePublished - 1980
Externally publishedYes

Fingerprint

methanol extraction residue (MER) tubercle bacillus fraction
Active Immunotherapy
Mycobacterium bovis
Combination Drug Therapy
Breast Neoplasms
Survival
Poisons
Vincristine
Methotrexate
Fluorouracil
Immunotherapy
Doxorubicin
Cyclophosphamide
Gastrointestinal Tract
Appointments and Schedules
Bone Marrow
Control Groups
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Alternating noncross-resistant combination chemotherapy and active nonspecific immunotherapy with BCG or MER-BCG for advanced breast carcinoma. / Blumenschein, G. R.; Hortobagyi, G. N.; Richman, S. P.; Gutterman, J. U.; Tashima, C. K.; Buzdar, A. U.; Burgess, M. A.; Livingston, Robert B; Hersh, Evan M.

In: Cancer, Vol. 45, No. 4, 1980, p. 742-749.

Research output: Contribution to journalArticle

Blumenschein, G. R. ; Hortobagyi, G. N. ; Richman, S. P. ; Gutterman, J. U. ; Tashima, C. K. ; Buzdar, A. U. ; Burgess, M. A. ; Livingston, Robert B ; Hersh, Evan M. / Alternating noncross-resistant combination chemotherapy and active nonspecific immunotherapy with BCG or MER-BCG for advanced breast carcinoma. In: Cancer. 1980 ; Vol. 45, No. 4. pp. 742-749.
@article{ff06597fca2b42db8b21d12583b9e56f,
title = "Alternating noncross-resistant combination chemotherapy and active nonspecific immunotherapy with BCG or MER-BCG for advanced breast carcinoma",
abstract = "One hundred fifty-six evaluable patients with metastatic breast cancer were treated with vincristine, Adriamycin and cyclophosphamide alternating at fixed intervals with 5-FU and methotrexate. Immunotherapy with BCG or MER-BCG was administered to all patients in two consecutive treatment programs. Overall objective response rate and complete response rate were 67{\%} and 20{\%}, respectively. These were not significantly different between the two immunotherapeutic groups. The median time to progression was sixteen-and-a-half months from initiation of therapy. The median survival of all patients was 21 months and that of responder was 26 months. Response rates, time to progression, and survival showed no significant advantage over a recent historical control group treated with FAC-BCG. Toxicitiy related to the gastrointestinal tract and bone marrow was considerably higher in this protocol than in the FAC combinations. MER at the dose, route, and schedule administered in this protocol caused excessive local and systemic toxic reactions. The alternative use of these noncross-resistant combinations in advanced breast cancer is not superior to combination chemotherapy used in the traditional manner.",
author = "Blumenschein, {G. R.} and Hortobagyi, {G. N.} and Richman, {S. P.} and Gutterman, {J. U.} and Tashima, {C. K.} and Buzdar, {A. U.} and Burgess, {M. A.} and Livingston, {Robert B} and Hersh, {Evan M}",
year = "1980",
doi = "10.1002/1097-0142(19800215)45:4<742::AID-CNCR2820450422>3.0.CO;2-X",
language = "English (US)",
volume = "45",
pages = "742--749",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "4",

}

TY - JOUR

T1 - Alternating noncross-resistant combination chemotherapy and active nonspecific immunotherapy with BCG or MER-BCG for advanced breast carcinoma

AU - Blumenschein, G. R.

AU - Hortobagyi, G. N.

AU - Richman, S. P.

AU - Gutterman, J. U.

AU - Tashima, C. K.

AU - Buzdar, A. U.

AU - Burgess, M. A.

AU - Livingston, Robert B

AU - Hersh, Evan M

PY - 1980

Y1 - 1980

N2 - One hundred fifty-six evaluable patients with metastatic breast cancer were treated with vincristine, Adriamycin and cyclophosphamide alternating at fixed intervals with 5-FU and methotrexate. Immunotherapy with BCG or MER-BCG was administered to all patients in two consecutive treatment programs. Overall objective response rate and complete response rate were 67% and 20%, respectively. These were not significantly different between the two immunotherapeutic groups. The median time to progression was sixteen-and-a-half months from initiation of therapy. The median survival of all patients was 21 months and that of responder was 26 months. Response rates, time to progression, and survival showed no significant advantage over a recent historical control group treated with FAC-BCG. Toxicitiy related to the gastrointestinal tract and bone marrow was considerably higher in this protocol than in the FAC combinations. MER at the dose, route, and schedule administered in this protocol caused excessive local and systemic toxic reactions. The alternative use of these noncross-resistant combinations in advanced breast cancer is not superior to combination chemotherapy used in the traditional manner.

AB - One hundred fifty-six evaluable patients with metastatic breast cancer were treated with vincristine, Adriamycin and cyclophosphamide alternating at fixed intervals with 5-FU and methotrexate. Immunotherapy with BCG or MER-BCG was administered to all patients in two consecutive treatment programs. Overall objective response rate and complete response rate were 67% and 20%, respectively. These were not significantly different between the two immunotherapeutic groups. The median time to progression was sixteen-and-a-half months from initiation of therapy. The median survival of all patients was 21 months and that of responder was 26 months. Response rates, time to progression, and survival showed no significant advantage over a recent historical control group treated with FAC-BCG. Toxicitiy related to the gastrointestinal tract and bone marrow was considerably higher in this protocol than in the FAC combinations. MER at the dose, route, and schedule administered in this protocol caused excessive local and systemic toxic reactions. The alternative use of these noncross-resistant combinations in advanced breast cancer is not superior to combination chemotherapy used in the traditional manner.

UR - http://www.scopus.com/inward/record.url?scp=0018843958&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018843958&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(19800215)45:4<742::AID-CNCR2820450422>3.0.CO;2-X

DO - 10.1002/1097-0142(19800215)45:4<742::AID-CNCR2820450422>3.0.CO;2-X

M3 - Article

VL - 45

SP - 742

EP - 749

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 4

ER -